TC/T2T (n=80) | UC (n=80) | Total (n=160) | |
Age (years)* | 37.6 (10.8) | 38.1 (11.4) | 37.9 (11.0) |
Sex (Male) | 45 (56.2%) | 37 (46.2%) | 82 (51.2%) |
Smoking status (current) | 29 (36.2%) | 32 (40.0%) | 61 (38.1%) |
University studies † | 57 (71.2%) | 42 (52.2%) | 99 (61.9%) |
Disease duration (years) | 4.2 (6.56) | 3.3 (5.83) | 3.7 (6.20) |
Radiographic sacroiliitis | 42 (52.5%) | 33 (41.2%) | 75 (46.9%) |
MRI sacroiliitis | 63 (78.8%) | 68 (85.0%) | 131 (81.9%) |
HLA B27 positive | 62 (77.5%) | 58 (72.5%) | 120 (75.0%) |
History of anterior uveitis† | 16 (20.0%) | 6 (7.5%) | 22 (13.8%) |
Good NSAID response | 63 (78.8%) | 55 (68.8%) | 118 (73.8%) |
ASDAS | 3.0 (0.7) | 3.0 (0.6) | 3.0 (0.7) |
BASDAI (n=80/79) | 5.2 (1.7) | 5.2 (1.9) | 5.2 (1.8) |
CRP (mg/L) | 9.2 (9.8) | 7.4 (10.5) | 8.3 (10.1) |
ASAS-Health Index (0–17) (n=80/78) | 8.2 (3.8) | 9.0 (3.6) | 8.6 (3.70) |
NSAID score (last 3 months) | 32.7 (35.4) | 37.5 (36.6) | 35.1 (36.0) |
*Numerical variables are presented as means (SD) and categorical variables as n (percentage).
†Significantly imbalanced variables; other imbalanced variables at baseline were gastrointestinal events in relation to NSAIDs, Physician Global and Rehabilitation days (see online supplemental file 3).
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; NSAID, non-steroidal anti-inflammatory drugs.